Ultrasound‐guided foam sclerotherapy for primary small saphenous vein insufficiency

Wu, Zhoupeng; Ma, Ying

doi:10.1111/ans.16470

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of truncal vein treatments involve foam polidocanol with a concentration ranging from 1% to 3%. The hyperpigmentation rates reported by all RCTs and non‐RCTs during this analysis (liquid and foam) were 7%–45.8% for polidocanol 1%, 21–26 16%–17% for polidocanol 2% 27,28 and 7.4%–32.5% for polidocanol 3% 21,22,24,25,28–30 …”

Section: Resultsmentioning

confidence: 72%

“…The hyperpigmentation rates reported by all RCTs and non-RCTs during this analysis (liquid and foam) were 7%-45.8% for polidocanol 1%, [21][22][23][24][25][26] 16%-17% for polidocanol 2% 27,28 and 7.4%-32.5% for polidocanol 3%. 21,22,24,25,[28][29][30] One randomized study compared polidocanol 3% liquid and polidocanol 3% foam. The authors found slightly less hyperpigmentation in the foam group than in the liquid group (7.4% vs. 9.6%) with almost the same injected volumes (liquid or emulsified foam).…”

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

See 1 more Smart Citation

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Skin hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches and truncal varices with polidocanol‐containing sclerosants was performed. Reported incidence rates, follow‐up periods and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for polidocanol 0.5% (liquid and foam) and between 13% and 73% for polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for polidocanol 1% (liquid and foam), from 16% to 17% for polidocanol 2% (foam) and from 7.4% to 32.5% for polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam polidocanol 1%–3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol‐related sclerotherapy are poor and should be improved by higher‐quality research.

show abstract

Section: Resultsmentioning

confidence: 72%

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…El 60.9% de los pacientes reportó uso adherente de elastocompresión, ligeramente más alto a lo encontrado en otros trabajos donde se mencionan adherencias alrededor del 40 al 50% 18,19 . Se considera importante este hallazgo en esta población, dado que este es un factor protector para la progresión de la enfermedad venosa, como bien ha sido mencionado en otros trabajos e, incluso, en las guías de manejo internacional recientes [1][2][3][4] .…”

Section: Discussionunclassified

Caracterización de safenectomía menor por insuficiencia en Colombia: seguimiento de 3 a 5 años

Correa-Posada,

García-Vélez,

García-Martínez

et al. 2023

RMA

View full text Add to dashboard Cite

La safenectomía de vena safena menor y varicectomía son una opción de manejo viable para las várices. En Colombia, existen pocos estudios que hagan seguimiento a largo plazo. Se evaluó el resultado a largo plazo, síntomas y recurrencias de safenectomía de safena menor. Objetivo: Determinar las características sociodemográficas, clínicas y ecográficas posteriores a safenectomía de safena menor a mediano y largo plazo. Método: Estudio prospectivo, seguimiento de 3 a 5 años en pacientes sometidos a safenectomía de vena safena menor y varicectomía, intervenidos entre 2016 y 2018 en Colombia. Resultados: Se revisaron 46 pacientes. 17.4% persistía con síntomas asociados a enfermedad venosa, 84.7% tenía un estadio clínico CEAP C1-C2. El estudio Doppler encontró safena menor insuficiente recidivada en 32% de los casos, 50% presentaba tributarias insuficientes dependientes de safena menor. Conclusiones: Se encontró una proporción de recurrencias similar a otros estudios en el seguimiento a largo plazo, y similar a los procedimientos endovasculares (30% y 65% respectivamente).

show abstract

A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Cohort Studies to Study the Efficacy of Ultrasound-Guided Foam Sclerotherapy for Varicose Vein Treatment

et al. 2023

View full text Add to dashboard Cite

Ultrasound‐guided foam sclerotherapy for primary small saphenous vein insufficiency

Abstract: This study shows that ultrasound‐guided foam sclerotherapy is a safe and effective method for symptomatic small saphenous vein insufficiency, with less adverse reactions and better effects.

Cited by 4 publications

References 16 publications

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Caracterización de safenectomía menor por insuficiencia en Colombia: seguimiento de 3 a 5 años

A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Cohort Studies to Study the Efficacy of Ultrasound-Guided Foam Sclerotherapy for Varicose Vein Treatment

Contact Info

Product

Resources

About